MiMedx Group, Inc.

As of October 31, 2025, MiMedx Group, Inc. shows a mildly bullish trend driven by positive weekly MACD and Bollinger Bands, despite mixed signals from daily moving averages and monthly RSI, while it has outperformed the S&P 500 recently but underperformed year-to-date.

As of October 31, 2025, MiMedx Group, Inc. is fairly valued with a P/E ratio of 24, showing strong historical performance but facing recent challenges reflected in a year-to-date return of -20.06%.

As of October 31, 2025, MiMedx Group, Inc. shows a mildly bullish trend, supported by positive MACD and Bollinger Bands signals, despite a mildly bearish daily moving average and underperformance over the year.

As of October 31, 2025, MiMedx Group, Inc. shows a mildly bullish technical trend overall, with positive weekly indicators despite mixed signals from daily and monthly analyses, and a recent performance of 13.17% over the past week, significantly outperforming the S&P 500.

As of October 31, 2025, MiMedx Group, Inc. is fairly valued with a P/E ratio of 24 and has shown strong short-term performance, but has underperformed year-to-date compared to the S&P 500.

As of October 31, 2025, MiMedx Group, Inc. shows a mildly bullish trend driven by positive weekly indicators, despite mildly bearish monthly signals, and has outperformed the S&P 500 in the past week and month, but underperformed year-to-date and over the past year.

As of October 31, 2025, MiMedx Group, Inc. is fairly valued with a P/E ratio of 24 and an EV to EBITDA of 14.64, both below peer averages, while demonstrating strong profitability metrics and a significant three-year return of 158.45%, despite facing recent challenges reflected in a year-to-date return of -20.48%.

As of October 10, 2025, MiMedx Group, Inc. is in a bearish trend with moderate strength, indicated by bearish signals from moving averages and RSI, despite a positive yearly return, it has significantly underperformed the S&P 500 year-to-date.

As of October 10, 2025, MiMedx Group, Inc. is in a bearish trend with weak strength, indicated by negative signals from moving averages and Bollinger Bands, while underperforming the S&P 500 with a year-to-date return of -31.91%.

As of October 10, 2025, MiMedx Group, Inc. is in a bearish trend with weak strength, indicated by negative moving averages and mixed signals from the MACD, underperforming the S&P 500 with a year-to-date return of -31.91%.

As of July 7, 2025, MiMedx Group, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 year-to-date at -25.68% compared to its 12.22% gain, while slightly lagging over the past year with a return of 15.70% versus the S&P 500's 17.14%.

As of July 30, 2025, MiMedx Group, Inc. is fairly valued with a P/E ratio of 24 and has underperformed the S&P 500 year-to-date with a return of -25.68%, but has outperformed it over three years with a return of 119.33%.

As of February 26, 2025, MiMedx Group, Inc. is fairly valued with a P/E ratio of 24 and an EV to EBITDA of 14.64%, showing relative undervaluation compared to peers like LeMaitre Vascular, Inc., but has underperformed the S&P 500 with a 13.54% decline over the past year.

As of May 9, 2025, MiMedx Group, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and Bollinger Bands across multiple time frames, suggesting continued weakness in the stock.

MiMedx Group, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $88 million and a net profit of $7 million. Key metrics include a market cap of $868.60 million, a P/E ratio of 24.00, and a return on equity of 19.84%.

As of Jun 18, MiMedx Group, Inc. has a market capitalization of 868.60 million, with net sales of 352.38 million and a net profit of 39.96 million over the latest four quarters. The balance sheet shows shareholder's funds of 193.11 million and total assets of 263.92 million.